The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

A new microfluidic device promises to revolutionize kidney disease screening by enabling rapid, accurate, and low-cost ...

Patients with macroalbuminuria faced a significantly higher risk of major adverse cardiovascular events (MACE), heart failure ...

In acute kidney injury, certain biomarkers—such as urine albumin-to-creatinine ratio and epidermal growth factor—are linked with likelihood of eGFR nonrecovery.

Simultaneous treatment start with finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Berlin Saturday, June 7, 2025, 1 ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

The VALIANT Phase 3 trial shows that pegcetacoplan significantly reduces proteinuria and stabilises kidney function in ...